Izvorni znanstveni članak
https://doi.org/10.20471/LO.2019.47.02-03.09
Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb
Marija Gamulin
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Milena Gnjidić
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Deni Rkman
; School of Medicine, University of Zagreb, Zagreb, Croatia
Marko Bebek
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Sažetak
Field of metastatic renal cell cancer (mRCC) treatments is now evolving at a rapid and unprecedented pace. Nivolumab prolongs survival in patients with metastatic kidney cancer with a favorable safety profile as demonstrated in the Check-Mate 025 clinical trial. Nivolumab compared to everolimus prolonged survival in patients with mRCC while exibiting favorbale safety profile. In this study we present the results of nivolumab treatment in patients with mRCC within named patient program (NPP) at UHC Zagreb. In 30% of included patients survival was longer than 30 months and 16.6% patients had a complete response.
Ključne riječi
metastatic kidney cancer; nivolumab; second line
Hrčak ID:
233608
URI
Datum izdavanja:
28.1.2020.
Posjeta: 1.371 *